{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007468","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.826420+00:00","generated_at":"2026-05-16T01:49:49.748511+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MangoRx's new $99/mo injectable TRT sees 336% MoM sales growth, 54% CAC drop","bullets":["Month-over-month sales of injectable TRT program increased 336% since mid-December 2025 launch.","Customer acquisition cost reduced by 54% over the same period.","Global TRT market valued at $2.11-2.2B in 2025, expected CAGR 3.9% (TBRC report).","CEO Jacob Cohen: TRT is key strategic focus; platform evolving to broader men's health."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007468","json":"https://secwatch.observer/filing/0001493152-26-007468.json","markdown":"https://secwatch.observer/filing/0001493152-26-007468.md","text":"https://secwatch.observer/filing/0001493152-26-007468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315226007468/0001493152-26-007468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315226007468/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:49:49.748511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}